“Predictmedix"s cutting-edge AI technology for infection and impairment testing gaining traction - Proactive Investors USA & Canada” plus 3 more

---

• Predictmedix"s cutting-edge AI technology for infection and impairment testing gaining traction - Proactive Investors USA & Canada
• Global Virology and Bacteriology Market Competition, Forecast & Opportunities, 2020-2025 - Molecular Diagnostics, Immunoassays, Diagnostic Imaging, Information Technology - ResearchAndMarkets.com - The Baytown Sun
• VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency - The Baytown Sun
• Global Tuberculosis Diagnostics Market Report 2020-2025: Increasing Prevalence of Multi-Drug Resistant (MDR) Tuberculosis is Driving Market Growth - ResearchAndMarkets.com - Odessa American

Predictmedix"s cutting-edge AI technology for infection and impairment testing gaining traction - Proactive Investors USA & Canada Posted: 23 Nov 2020 03:51 AM PST Focused on technologies that eliminates or moderates need for biologics Currently has signed agreements with four companies to distribute and re-sell its solutions Firm has filed two US patents for symptom screening technology and two more for remote patient monitoring What Predictmedix does: Predictmedix Inc (CSE:PMED) (OTCQB:PMEDF), formerly known as Cultivar Holdings, became a public company in 2019 and aims to be a market leader in the workplace health and safety (H&S) space - a sector where tech solutions have been largely absent until now. It is an artificial intelligence (AI) company, which is developing disruptive tools for impairment testing and health care aimed at use across various workplaces and by law enforcement agents. The technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous data points. Amid the current pandemic, the team realized the same multi-spectral imaging and AI methods could be deployed to identify coronavirus (COVID-19) symptoms. People walk through modules (like a tunnel) linked to cloud software and, within fractions of a second, a green or red light appears, identifying those who are exhibiting symptoms. The firm's technology is focused broadly on four areas - impairment, infectious disease, mental health and remote patient monitoring/telehealth. Dr Rahul Kushwah, president and COO of Predictmedix says the market opportunity across this spectrum is enormous - up to an eye-watering US$300 billion. The company was co-founded by Kushwah, a former Professor at the University of Ottawa's medical school and a scientist with the government of Canada (National Research Council) turned entrepreneur, and capital markets specialist Sheldon Kales who is a serial entrepreneur and has led the transition of several companies from private space to public trading. How is it doing: This year is perhaps best described as Predictmedix progressing its aim of getting its products and ideas "out there". In August, the company announced that its COVID-19 screening technology, along with its alcohol and impairment tech, was set to be deployed at Indian Oil Corporation Ltd (NSE:IOC), which had revenue last year of over US85 billion. The same month, the company said it was rolling out the coronavirus screening tech at the Flow Water facility in Ontario and at a 24-hour pharmacy in Montreal. The deployment at Flow Water's Aurora facility came as part of Predictmedix's contract with North American exhibit fabricating firm Juiceworks Exhibits. And recently, on November 19, it announced another India deal via a tie-up with the country's premier defence technology company PARAS in a bid to launch its AI screening tech in the government and public sector in South Asia. Back in July, the group struck a milestone sales deal with UK-based distributor Taurus Medical Solutions for a 12-month contract, beginning on July 6, with an option for renewal if a certain number of clients come onboard. The firm said Taurus' "large and diverse client base" in the UK, along with its relationship with the UK's National Health Service (NHS), offered a "great opportunity to roll out our technologies in the healthcare sector in the UK". The group also has the technology to create treatment programs specially tailored for patients, which expands Predictmedix into telehealth and telemedicine along with remote patient monitoring - an area becoming increasingly important, especially in this COVID-19 dominated world. Predictmedix acquired Mobile Wellbeing in June this year and plans to integrate it with the company's existing artificial intelligence-driven rapid screening system for infectious diseases. The firm is eying retirement residences and the Long Term Care (LTC) market. Inflection points: More sales momentum Developments and advances in capability in the group's technology What the boss says: After the PARAS deal, CEO Dr Rahul Kushwah spoke to Proactive and noted: "India is a country with over 1 billion people so there is a lot of public infrastructure....and it actually presents to us a great business opportunity, especially to target the government and public sector." He added: "They (PARAS) can take care of all the engineering, all the fabrication..there is never going to be a bottle-neck there because that is something they're good at. That is something they do on a daily basis and from the other end, from the business standpoint, they have identified a huge business opportunity which they can capitalize on using our technology." Contact the author at [email protected]

Global Virology and Bacteriology Market Competition, Forecast & Opportunities, 2020-2025 - Molecular Diagnostics, Immunoassays, Diagnostic Imaging, Information Technology - ResearchAndMarkets.com - The Baytown Sun Posted: 23 Nov 2020 07:46 AM PST DUBLIN--(BUSINESS WIRE)--Nov 23, 2020-- The "Global Virology and Bacteriology Market, by Technology (Molecular Diagnostics, Immunoassays, Diagnostic Imaging, Information Technology), by Disease, by End User, by Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering. The Global Virology and Bacteriology Market is expected to grow at a CAGR of around 12% during 2021 - 2025. The Global Virology and Bacteriology Market is driven by rising population getting affected by viral and bacterial infections. Moreover, governments across the globe are investing more on healthcare infrastructure, which is positively impacting the market growth. Also, continuous technological innovations in research and development activities is further expected to bolster the growth of the market over the next few years. The Global Virology and Bacteriology Market is segmented based on technology, disease, end-user, company, and region. Based on technology, the market can be categorized into molecular diagnostics, immunoassays, diagnostic imaging, and information technology. Out of these, the molecular diagnostics segment dominated the market in 2019 and is expected to maintain its leading position during the forecast period as well. This can be ascribed to the fact that this technology allows the detection of lower amount of infectious agents, thereby detecting the infection at an early stage than was previously possible. Major players operating in the Global Virology and Bacteriology Market include Fujirebio Diagnostics Inc., Cepheid, Diasorin, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Scienion AG, Grifols, Qiagen, Eiken Chemical Co Ltd, Sequenom, bioMerieux SA, Siemens AG, Hologic Inc., Diamedix Inc., Leica Biosystems Nussloch GmbH, F. Hoffmann-La Roche Ltd, Abbott, GSK Biologicals, Roche, Affymetrix, among others. The companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers, acquisitions, collaborations and partnerships. Years considered for this report: Historical Years: 2015 - 2018 Base Year: 2019 Estimated Year: 2020 Forecast Period: 2021 - 2025 Key Topics Covered: 1. Product Overview 2. Research Methodology 3. Impact of COVID-19 on Global Virology and Bacteriology Market 4. Executive Summary 5. Voice of Customer 6. Global Virology and Bacteriology Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Technology (Molecular Diagnostics, Immunoassays, Diagnostic Imaging, Information Technology) 6.2.2. By Disease (Respiratory System, Urinary Tract, And Bloodstream Diseases; Gastrointestinal and Periodontal Diseases; Sexually Transmitted Diseases) 6.2.3. By End User (Clinics, Hospitals, Diagnostic Centers, Research Laboratories, And Blood Banks) 6.2.4. By Company (2019) 6.2.5. By Region 6.3. Market Attractiveness Index 7. Asia-Pacific Virology and Bacteriology Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Technology 7.2.2. By Disease 7.2.3. By End User 7.2.4. By Country 7.3. Asia-Pacific: Country Analysis 8. Europe Virology and Bacteriology Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Technology 8.2.2. By Disease 8.2.3. By End User 8.2.4. By Country 8.3. Europe: Country Analysis 9. North America Virology and Bacteriology Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Technology 9.2.2. By Disease 9.2.3. By End User 9.2.4. By Country 9.3. North America: Country Analysis 10. South America Virology and Bacteriology Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Technology 10.2.2. By Disease 10.2.3. By End User 10.2.4. By Country 10.3. South America: Country Analysis 11. Middle East and Africa Virology and Bacteriology Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Technology 11.2.2. By Disease 11.2.3. By End User 11.2.4. By Country 11.3. MEA: Country Analysis 12. Market Dynamics 12.1. Drivers 12.2. Challenges 13. Market Trends & Developments 14. Patent Analysis 15. Competitive Landscape 15.1. Fujirebio Diagnostics Inc. 15.2. Cepheid Inc. 15.3. DiaSorin S.p.A. 15.4. Bio-Rad Laboratories Inc. 15.5. Thermo Fisher Scientific Inc. 15.6. Scienion AG 15.7. Grifols S.A. 15.8. Qiagen N.V. 15.9. Eiken Chemical Co. Ltd. 15.10. Sequenom Inc. 15.11. bioMerieux SA 15.12. Siemens AG 15.13. Hologic Inc. 15.14. Diamedix Corporation 15.15. Leica Biosystems Nussloch GmbH 15.16. F. Hoffmann-La Roche AG 15.17. Abbott Laboratories 15.18. GSK Biologicals SA 16. Strategic Recommendations For more information about this report visit https://www.researchandmarkets.com/r/avjjn5 View source version on businesswire.com:https://www.businesswire.com/news/home/20201123006029/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PHARMACEUTICAL SCIENCE HEALTH RESEARCH SOURCE: Research and Markets Copyright Business Wire 2020. PUB: 11/23/2020 10:46 AM/DISC: 11/23/2020 10:46 AM http://www.businesswire.com/news/home/20201123006029/en

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency - The Baytown Sun Posted: 23 Nov 2020 05:01 AM PST CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 23, 2020-- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the Company's 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. "We believe our 3-antigen prophylactic hepatitis B vaccine has the potential to be an important intervention in the fight to eliminate Hepatitis B infections and this MAA submission is a significant milestone for the product and VBI more generally," said Jeff Baxter, President & CEO. "We are committed to working collaboratively with the EMA throughout the regulatory process to provide access to this vaccine in Europe. As part of the global commercialization strategy for this vaccine, we also remain on track to submit the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the next couple of weeks." About Hepatitis B Hepatitis B is one of the world's most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma. About VBI's 3-Antigen Hepatitis B Vaccine This vaccine is the only 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel. In December 2017, VBI initiated patient dosing in a global Phase 3 clinical program that consisted of two concurrent pivotal studies: PROTECT, a safety and immunogenicity study, and CONSTANT, a lot-to-lot consistency study. Data from both the PROTECT study and the CONSTANT study, which were announced in June 2019 and January 2020, respectively, comprise the basis for the regulatory submissions in the U.S., Europe, and Canada. This vaccine is sold under the name Sci-B-Vac® in Israel. To learn more about VBI's 3-antigen Hepatitis B vaccine visit: https://www.vbivaccines.com/sci-b-vac/ About VBI Vaccines Inc. VBI Vaccines Inc. ( Nasdaq: VBIV ) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel. Website Home: http://www.vbivaccines.com/ News and Insights: http://www.vbivaccines.com/wire/ Investors: http://www.vbivaccines.com/investors/ Cautionary Statement on Forward-looking Information Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law. View source version on businesswire.com:https://www.businesswire.com/news/home/20201123005591/en/ CONTACT: VBI Nicole Anderson Director, Corporate Communications & IR Phone: (617) 830-3031 x124 Email:IR@vbivaccines.com KEYWORD: EUROPE UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: RESEARCH INFECTIOUS DISEASES FDA CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE ONCOLOGY SOURCE: VBI Vaccines Inc. Copyright Business Wire 2020. PUB: 11/23/2020 08:00 AM/DISC: 11/23/2020 08:01 AM http://www.businesswire.com/news/home/20201123005591/en

Global Tuberculosis Diagnostics Market Report 2020-2025: Increasing Prevalence of Multi-Drug Resistant (MDR) Tuberculosis is Driving Market Growth - ResearchAndMarkets.com - Odessa American Posted: 23 Nov 2020 08:34 AM PST DUBLIN--(BUSINESS WIRE)--Nov 23, 2020-- The "Tuberculosis Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global tuberculosis diagnostics market is currently witnessing strong growth. The market to register a CAGR of around 3% during 2020-2025. Tuberculosis (TB) refers to an infectious bacterial disease that primarily affects the lungs (pulmonary), along with other parts of the body (extrapulmonary). The infection is diagnosed via a Mantoux tuberculin skin test (TST) or the TB blood test. Additional tests are required to confirm TB disease, depending on the infected organs. In the case of pulmonary TB, chest radiography is performed for detecting chest abnormalities, along with acid-fast staining and microscopic examination of the patient's sputum. Extrapulmonary TB can be diagnosed using CT, MRI or ultrasound scans, endoscopy, laparoscopy, urine and blood tests, biopsies, and lumbar punctures. The increasing prevalence of multi-drug resistant (MDR) tuberculosis across the globe is one of the key factors driving the growth of the market. MDR tuberculosis is caused by bacteria that are resistant to isoniazid and rifampicin, which are considered to be among the most potent antimicrobial drugs for TB. Furthermore, the availability of technologically advanced Point-of-Care (POC) diagnostic methods is also providing a boost to the market growth. Advanced diagnostic methods, such as Nucleic acid amplification tests (NAATs) and Interferon-Gamma Release Assay (IGRA), are more accurate, convenient, and provide prompt results in comparison to the traditionally used techniques. Additionally, significant improvements in the healthcare infrastructure, along with the growing awareness among the masses about various diagnostic procedures, are acting as another growth-inducing factor. Other factors, including the rising geriatric population and increasing healthcare expenditure and government initiatives and investments to promote research and development (R&D) activities, are projected to drive the market further. Key Questions Answered in this Report: How has the global tuberculosis diagnostics market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the disease stage? What is the breakup of the market based on the test type? What is the breakup of the market based on the end-user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global tuberculosis diagnostics market and who are the key players? What is the degree of competition in the industry? Key Topics Covered: 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.4 Market Estimation 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Tuberculosis Diagnostics Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Forecast 6 Market Breakup by Disease Stage 6.1 Latent TB 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Active TB 7 Market Breakup by Test Type 7.1 Radiographic Test 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Laboratory Test 7.2.1 Market Trends 7.2.2 Major Types 7.2.2.1 Smear Microscopy 7.2.2.2 Culture-based Test 7.2.3 Market Forecast 7.3 Nucleic Acid Testing 7.4 Cytokine Detection Test 7.5 Drug Resistance Test 7.6 Others 8 Market Breakup by End-User 8.1 Hospitals and Clinics 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Diagnostics and Research Laboratories 8.3 Others 9 Market Breakup by Region 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 13 Price Indicators 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players Abbott Laboratories Alere Inc. Becton Dickinson and Company BioMerieux Cepheid Inc. Epistem Ltd. Roche Holding AG Hain Lifescience GmbH Hologic Inc. QIAGEN GmbH Siemens Thermo Fisher Scientific Inc. For more information about this report visit https://www.researchandmarkets.com/r/tzo6dh View source version on businesswire.com:https://www.businesswire.com/news/home/20201123006084/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH RADIOLOGY PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2020. PUB: 11/23/2020 11:34 AM/DISC: 11/23/2020 11:34 AM http://www.businesswire.com/news/home/20201123006084/en Copyright Business Wire 2020. © 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

You are subscribed to email updates from "infection inc" - Google News. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States